The drugmaker Ely Lilly (LLY -4.93%) has had a very successful run over the long run. Shares currently trade around $818 and are up 20,030% over the past 40 years. The stock has also performed well this year, rising roughly 36% (as of Nov. 14), ahead of the broader market.Given that Eli Lilly has been public for roughly seven decades, it's no surprise that it has conducted a few stock splits. When a company does a split, the amount of a shareholder's equity doesn't change but the number of shares does. Comp ...

In a first-of-its-kind study, tirzepatide also alleviated heart failure symptoms and physical limitationsPatients on tirzepatide experienced improved exercise capacity, greater weight loss and reduced systemic inflammation Lilly has initiated submissions for tirzepatide for the treatment of HFpEF and obesity to global regulatory agenciesINDIANAPOLIS, Nov. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from the SUMMIT Phase 3 trial showing tirzepatide significantl ...

Key TakeawaysEli Lilly has joined Johnson & Johnson in filing a lawsuit against the federal government over a decades-old drug discounting program.The companies have said the 340B program, which requires drugmakers to sell discounted medications to certain medical facilities, needs changes.The Health Resources and Services Administration, however, has rejected the companies' proposed changes to the program. Eli Lilly (LLY) became the second drugmaker in recent days to sue the U.S. government for rejecting t ...

SURMOUNT-1 results show a 94% reduction in risk of progression to type 2 diabetes across all pooled doses of tirzepatide compared to placebo over three yearsResults suggest one new case of diabetes could be prevented for every nine patients treated with tirzepatideParticipants treated with tirzepatide had an average weight reduction of 22.9% (15 mg dose)INDIANAPOLIS, Nov. 13, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today detailed results from the Phase 3 SURMOUNT-1 three-year study ...

If Wall Street's right, investors will get a lot more than just rising dividend payments from this pair.Finding stocks that could quickly double or triple your money isn't hard. Just about every day, a Wall Street analyst issues a price target that suggests a relatively small and unestablished company could double or triple your money. Usually, though, the word "could" is working way too hard for such a risky investment to make sense for most investors.If you want to avoid the riskiest corners of the stock ...

RISES OVER 1.6% AT IT’S HIGH FOR THE DAY AFTER EARLY DROP AND THE POWER INFLOW SIGNALEli Lilly & Company LLY today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. Today, at 10:35 AM on November 12th, a significant trading signal occurred for Eli Lilly as it demonstrated a Power Inflow at a price of $816.14. This indicator is crucial for traders who want to know directionally where institutions and so-calle ...

Core Insights - Eli Lilly and Company (LLY) has experienced a 10.6% decline in stock price this month following disappointing third-quarter results, missing both earnings and sales estimates while lowering financial guidance for the year [1][2] Financial Performance - The total revenue guidance was narrowed from a range of $45.4 billion to $46.6 billion down to $45.4 billion to $46.0 billion, and earnings per share guidance was sharply cut from $16.10 to $16.60 to $13.02 to $13.52 due to IPR&D charges related to the acquisition of Morphic [2] - Despite the disappointing sales performance, Lilly's revenues were up 42% on an organic basis in the third quarter, with a projected year-over-year revenue growth of 50% in the fourth quarter [21] Product Performance - Mounjaro and Zepbound, key drugs for diabetes and obesity, generated sales of $11.0 billion in the first three quarters of 2024, accounting for approximately 45% of total revenues [6] - Sales of Mounjaro and Zepbound were impacted by inventory issues, with channel inventory decreasing at wholesalers in the third quarter [7] - Lilly is balancing demand and supply for these drugs and expects increased demand activities in the fourth quarter, which should benefit sales in 2025 [8] Competitive Landscape - Lilly's tirzepatide medicines face strong competition from Novo Nordisk's semaglutide products, which have also missed estimates for earnings and sales [10] - Other companies like Amgen and Viking Therapeutics are developing GLP-1-based candidates that could pose future competition to Mounjaro and Zepbound [11] Pipeline and Future Prospects - Lilly has received approvals for several new drugs, including Kisunla for Alzheimer's disease, and is investing in obesity treatments with 11 new molecules in clinical development [12][14] - The company is also developing tirzepatide for additional indications, which could further boost sales [9] Stock Performance and Valuation - Lilly's stock has risen 42.7% this year, outperforming the industry and the S&P 500 [15] - The stock is currently trading at a premium to the industry, with earnings estimates for 2024 declining from $15.80 to $13.19 per share over the past 30 days [17][18] Investor Sentiment - Despite recent declines, the company still has growth prospects as demand for Mounjaro and Zepbound remains strong, suggesting investors may consider holding the stock [22]

Conditions are getting a bit more challenging for the drugmaker.If you looked solely at its stock price, you might get the idea that Eli Lilly (LLY 4.28%) is having a bit of an off quarter. Over the past 30 days, its shares fell by about 10%, though they are still up by around 37% so far this year. And, if management is correct, one cloudy trend driving their recent decrease in performance is more likely to stick around than shareholders would prefer.Nonetheless, things aren't anywhere near as bad as they m ...

The good times aren't over, but the peak of the party might be passing.Eli Lilly (LLY 4.28%) and Novo Nordisk (NVO -0.40%), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both declined even as the rest of the market rose.Short-term price changes shouldn't have anything to do with an investment thesis for either stock. Still, investors sold shares in both for a reason. And there's a chance that the issue driving ...

The market's perception of the pharmaceutical company has undeniably shifted.Even a juggernaut like Eli Lilly (LLY 2.71%) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat, signaling that the market's reception to its financial performance was strongly negative.Shareholders discovered that there's reason to believe that a previously hypothesized risk is now real and that it presents a possible threat to ...